Because the drug vial docks directly into the injector casing rather than being drawn with a syringe, the need for pharmacist preparation is bypassed and availability via Pyxis is enabled. Furthermore, concealing the needle entirely inside the disc eliminates staff needlestick injury risks.
When given the choice after cycle six in clinical crossover studies, patients overwhelmingly selected the on-body injector over returning to manual syringe pushes. Prior exposure to modern diabetes devices and GLP-1s has conditioned patient psychology to favor discrete, low-gauge administration formats.
Although on-body delivery has historically been confined to diabetes or supportive care, its validation in anti-cancer therapeutics paves the way for broader oncology adoption. Clinicians anticipate this shift will encourage other pharmaceutical developers to move intravenous cancer regimens toward at-home and alternative-site platforms.
